Latest News
Nektar Therapeutics
- Nektar Therapeutics stock analysis: oversold technicals meet binary clinical risk
- Nektar Therapeutics: Downgrade To Hold On REZPEG Market Outlook Setback And More (NKTR)
- Nektar Discloses Phase 2b Data for REZPEG in Severe Alopecia Areata
- Nektar Therapeutics downgraded to Hold over saf...
- H.C. Wainwright reiterates Nektar Therapeutics stock rating on alopecia data
- Nektar Posted Promising Alopecia Results. Here's Why It Took A 22% Beating.
- Eli Lilly owes Nektar $90 mln in drug collaboration dispute, US jury says
- Nektar Therapeutics awarded $90M jury verdict against Eli Lilly over rezpegaldesleukin dispute
- Lilly ordered to pay Nektar $90M in damages over rezpeg dispute
- Nektar prevails in legal battle with Lilly over broken rezpeg partnership
- Why is Nektar Therapeutics stock climbing today?
- Eli Lilly Hit With $90M Verdict In Nektar's Rezpeg Breach Suit
Headlines from the last 30 days, linking to the original publishers. See all market news →